Hypertension - Pipeline Insight, 2024

This “Hypertension - Pipeline Insight, 2024” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hypertension: Understanding

Hypertension: Overview

Hypertension, commonly known as high blood pressure, is a chronic medical condition characterized by elevated pressure in the arteries, which can lead to serious health complications if left untreated. It is classified into primary hypertension, which has no identifiable cause and often develops gradually over many years, and secondary hypertension, which results from an underlying condition, such as kidney disease or hormonal disorders. Hypertension is a major risk factor for cardiovascular diseases, including heart attack and stroke, as well as kidney damage and vision loss. Hypertension, often referred to as the "silent killer," may not present noticeable signs or symptoms, particularly in its early stages, which makes regular monitoring essential. When symptoms do occur, they can include headaches, dizziness, shortness of breath, nosebleeds, and palpitations. In severe cases, individuals may experience blurred vision, chest pain, or fatigue, indicating potential damage to the heart or other organs. It's important to note that many people with hypertension may remain asymptomatic for years, underscoring the need for routine blood pressure checks to detect the condition early and prevent serious health complications.

The pathology of hypertension involves complex interactions between genetic, environmental, and physiological factors that lead to sustained elevations in arterial blood pressure. Central to this process is the dysfunction of the vascular system, particularly the endothelium, which regulates vascular tone and blood flow. In hypertension, factors such as oxidative stress, inflammation, and abnormal production of vasoactive substances (e.g., endothelin and nitric oxide) contribute to endothelial dysfunction and increased vascular resistance. Additionally, neurohumoral mechanisms, including the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system activation, play crucial roles in promoting vasoconstriction and fluid retention.

The treatment of hypertension typically involves a multifaceted approach, combining lifestyle modifications and pharmacological interventions to effectively manage blood pressure levels and reduce the risk of cardiovascular complications. Lifestyle changes, such as adopting a heart-healthy diet rich in fruits, vegetables, whole grains, and low-fat dairy (e.g., the DASH diet), maintaining a healthy weight, engaging in regular physical activity, and limiting alcohol intake and sodium consumption, are essential first steps.

"Hypertension - Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypertension pipeline landscape is provided which includes the disease overview and Hypertension treatment guidelines. The assessment part of the report embraces, in depth Hypertension commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve Hypertension.

Hypertension Emerging Drugs Chapters

This segment of the Hypertension report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hypertension Emerging Drugs

Seralutinib: Gossamer Bio

Seralutinib, developed by Gossamer Bio, is an inhaled medication designed to treat pulmonary arterial hypertension (PAH). It functions as an antagonist of several receptors, including platelet-derived growth factor receptors (PDGFRα and PDGFRβ), colony-stimulating factor 1 receptor (CSF1R), and c-KIT. This multi-target approach aims to mitigate the inflammatory and proliferative pathways that contribute to pulmonary vascular remodeling associated with PAH. Currently, the drug is in the Phase III stage of its development for the treatment of Pulmonary Arterial Hypertension.

AD-209: Addpharma Inc.

AD-209 is an investigational drug developed by Addpharma Inc., primarily targeting hypertension. It is part of a broader pipeline that includes various innovative medicines aimed at treating multiple conditions, including hyperlipidemia and diabetes. Currently, the drug is in the Phase III stage of its development for the treatment of Hypertension.

Zilebesiran: Alnylam Therapeutics

Zilebesiran is an investigational RNA interference (RNAi) therapeutic developed by Alnylam Therapeutics, specifically targeting hypertension. It is designed to inhibit the synthesis of angiotensinogen (AGT), a key precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a crucial role in blood pressure regulation. Zilebesiran works by utilizing RNAi technology to selectively reduce the production of AGT in the liver. This reduction leads to decreased levels of angiotensin II, a potent vasoconstrictor that contributes to elevated blood pressure. By lowering AGT synthesis, zilebesiran aims to achieve sustained reductions in blood pressure over time. Currently, the drug is in the Phase II stage of development to treat Hypertension.

LAM-001: ORPHAI THERAPEUTICS

LAM-001 is an investigational inhaled formulation of sirolimus (also known as rapamycin) developed by OrphAI Therapeutics. It is designed specifically for the treatment of pulmonary hypertension (PH) and bronchiolitis obliterans syndrome (BOS), conditions that can significantly impact lung function and patient quality of life. Currently, the drug is in the Phase II stage of development to treat Pulmonary Hypertension.

HS135: 35Pharma Inc.

HS135 is an investigational drug developed by 35Pharma Inc., focusing on the treatment of pulmonary hypertension (PH) and related cardiometabolic diseases. It is a multi-specific receptor ectodomain ligand trap designed to neutralize activins and growth differentiation factors (GDFs), which are validated drivers of these conditions. HS135 functions as a ligand trap that specifically targets and inhibits the activity of activins and GDFs, particularly activin A and GDF-8. By doing so, it aims to rebalance the signaling pathways involved in various pathologies associated with pulmonary hypertension and obesity-related heart failure. Currently, the drug is in the Phase I stage of development to treat Pulmonary Arterial Hypertension.

Hypertension: Therapeutic Assessment

This segment of the report provides insights about the different Hypertension drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hypertension

There are approx. 80+ key companies which are developing the therapies for Hypertension. The companies which have their Hypertension drug candidates in the most advanced stage, i.e. Phase III include, Gossamer Bio and Addpharma Inc.

Phases

The report covers around 100+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of:
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as:

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hypertension: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hypertension therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypertension drugs.

Hypertension Report Insights

• Hypertension Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hypertension Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hypertension drugs?
• How many Hypertension drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypertension?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hypertension therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hypertension and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Gossamer Bio
• Addpharma Inc.
• Insmed Incorporated
• Alnylam Pharmaceuticals
• 35Pharma Inc
• Pfizer
• Pharmosa Biopharm Inc.
• Guangzhou Magpie Pharmaceuticals Co., Ltd.
• Suzhou Sanegene Bio Inc.
• JW Pharmaceutical

Key Products

• Seralutinib
• AD-209
• Treprostinil Palmitil
• Zilebesiran
• HS135
• PF-07868489
• L608
• MN-08
• SGB-3908
• JW0104

This product will be delivered within 3-5 business days.